With compelling clinical data in the bank for patisiran, the first RNA interference (RNAi) drug to triumph in Phase III, Alnylam Pharmaceuticals Inc. is confident that if approved, payers will be prepared to pay a price that recognizes the value of its treatment for hereditary ATTR (hATTR) amyloidosis.
The company will file patisiran with regulatory authorities before the end of the year, with the goal of achieving approval...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?